Thessa Kroes

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism

P. Parren, R. G. Hibbert, A. Lingnau, 2020, Molecular Cancer Therapeutics.

Abstract 2391: DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models

P. Parren, A. Lingnau, J. Schuurman, 2019, Immunology.